東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

PPAR-gamma: A multifaceted transcrip...

Duan, Shengzhong.

FindBook

Google Book

Amazon

博客來

PPAR-gamma: A multifaceted transcription factor important in diabetes, cardiovascular disease, and cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	PPAR-gamma: A multifaceted transcription factor important in diabetes, cardiovascular disease, and cancer./
作者:	Duan, Shengzhong.
面頁冊數:	198 p.
附註:	Source: Dissertation Abstracts International, Volume: 67-02, Section: B, page: 0824.
Contained By:	Dissertation Abstracts International67-02B.
標題:	Health Sciences, Pharmacology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3208449
ISBN:	9780542568954

PPAR-gamma: A multifaceted transcription factor important in diabetes, cardiovascular disease, and cancer.
Duan, Shengzhong.

PPAR-gamma: A multifaceted transcription factor important in diabetes, cardiovascular disease, and cancer. - 198 p.

Source: Dissertation Abstracts International, Volume: 67-02, Section: B, page: 0824.

Thesis (Ph.D.)--University of Michigan, 2006.

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a nutrient-sensing transcription factor that associates with cardiovascular diseases and metabolic disorders. Its agonists, the thiazolidinediones (TZDs), are clinically used to treat type 2 diabetes. This thesis investigated the multifaceted functions of PPAR-gamma and the pharmacology of TZDs in insulin sensitivity, glucose homeostasis, adipogenesis, blood pressure regulation, tumorigenesis, and cardiac growth.

ISBN: 9780542568954Subjects--Topical Terms:

1017717
Health Sciences, Pharmacology.

PPAR-gamma: A multifaceted transcription factor important in diabetes, cardiovascular disease, and cancer.
LDR:03503nmm 2200349 4500 001 1825093
005 20061201092005.5
008 130610s2006 eng d
020 $a 9780542568954
035 $a (UnM)AAI3208449
035 $a AAI3208449
040 $a UnM $c UnM
100 1 $a Duan, Shengzhong. $3 1914117
245 1 0 $a PPAR-gamma: A multifaceted transcription factor important in diabetes, cardiovascular disease, and cancer.
300 $a 198 p.
500 $a Source: Dissertation Abstracts International, Volume: 67-02, Section: B, page: 0824.
500 $a Adviser: Richard M. Mortensen.
502 $a Thesis (Ph.D.)--University of Michigan, 2006.
520 $a Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a nutrient-sensing transcription factor that associates with cardiovascular diseases and metabolic disorders. Its agonists, the thiazolidinediones (TZDs), are clinically used to treat type 2 diabetes. This thesis investigated the multifaceted functions of PPAR-gamma and the pharmacology of TZDs in insulin sensitivity, glucose homeostasis, adipogenesis, blood pressure regulation, tumorigenesis, and cardiac growth.
520 $a We rescued the embryonic lethality of generalized PPAR-gamma deficiency using Cre-LoxP technology to preserve PPAR-gamma expression in the placenta (MORE-PGKO mice). These mice demonstrated that PPAR-gamma is required to maintain normal adiposity, insulin sensitivity, and blood pressure.
520 $a Administration of rosiglitazone, a TZD, to these PPAR-gamma deficiency mice improved glucose homeostasis in both males and females. In females, rosiglitazone stimulated fat growth and was sufficient to improve insulin sensitivity. Vaspin, but not likely leptin or adiponectin, is a candidate adipokine that is responsible for this insulin-sensitizing effect. In males, glucose homeostasis was improved independently of adipose tissue and insulin-sensitivity likely by improving beta-cell function. Surprisingly, rosiglitazone treatment of male MORE-PGKO mice led to the development liver tumors, suggesting a tumor suppressor function of PPAR-gamma.
520 $a To directly determine the role of PPAR-gamma in cardiac growth, we developed a cardiomyocyte-specific PPAR-gamma knockout (CM-PGKO) mouse model. Cardiomyocyte PPAR-gamma was required to suppress cardiac growth, embryonic gene expression, and nuclear-factor-kappa-B activity in vivo. Rosiglitazone induced cardiac hypertrophy at least partially independent of PPAR-gamma in cardiomyocytes and through different mechanisms from CM-PGKO. These data may provide guidance for designing new drugs with fewer cardiac side effects.
520 $a In order to distinguish TZDs' intrinsic effects on cardiomyocytes from their blood pressure-lowering effects, we monitored pressure overload (POL) and found that systolic pressure at later stages was the major determinant of cardiac hypertrophy. In contrast to pioglitazone and troglitazone, rosiglitazone did not inhibit POL-induced cardiac hypertrophy. Future studies comparing multiple TZDs are needed to understand the pharmacology of this effect and to explore the role of PPAR-gamma in POL-induced cardiac hypertrophy.
590 $a School code: 0127.
650 4 $a Health Sciences, Pharmacology. $3 1017717
650 4 $a Health Sciences, Pathology. $3 1017854
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Biology, Molecular. $3 1017719
690 $a 0419
690 $a 0571
690 $a 0992
690 $a 0307
710 2 0 $a University of Michigan. $3 777416
773 0 $t Dissertation Abstracts International $g 67-02B.
790 1 0 $a Mortensen, Richard M., $e advisor
790 $a 0127
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3208449